Tier 3 — preclinical

Effects of quercetin in preclinical models of Parkinson's disease: A systematic review

Camila de Oliveira Vian, Marcelo Augusto Germani Marinho, Magno da Silva Marques, Mariana Appel Hort, Marcos Freitas Cordeiro, Ana Paula Horn
Basic & clinical pharmacology & toxicology 2024 135(1):3-22

Bibliography

PubMed
PMID 38682342
DOI
10.1111/bcpt.14011
Funding
Indexed grant support: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brazil (CAPES) - Finance code 001. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignSystematic review of preclinical Parkinson-model studies
ModelPreclinical evidence synthesis
Sample26 studies, predominantly rats and mice
InterventionQuercetin formulations using oral or intraperitoneal dosing
DurationExperiment-specific durations
EndpointsInflammatory measures; Oxidative-stress measures

What the study showed, in plain terms

Published in 2024, this source examined brain, cognition and sleep. Design: Systematic review of preclinical Parkinson-model studies. Sample/model: 26 studies, predominantly rats and mice. The exposure or intervention was Quercetin formulations using oral or intraperitoneal dosing. Follow-up or treatment period: Experiment-specific durations.

The review describes favorable oxidative, inflammatory, and neuronal findings in experimental Parkinson models.

Animal induction models, wide dose ranges, and differing delivery routes do not establish an effective or safe human treatment.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Brain Fog, Memory and Sleep: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The review describes favorable oxidative, inflammatory, and neuronal findings in experimental Parkinson models.
  • The recorded outcome domains were Inflammatory measures; Oxidative-stress measures.
  • The result applies to the tested exposure: Quercetin formulations using oral or intraperitoneal dosing; Experiment-specific durations.

What this study can and cannot tell us

  • Animal induction models, wide dose ranges, and differing delivery routes do not establish an effective or safe human treatment.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 3
Effects of quercetin and its derivatives in in vivo models of neuroinflammation: A systematic review and meta-analysis
Michele Goulart Dos Santos et al. · Neural regeneration research · 2026
Tier 3
Quercetin in Animal Models of Alzheimer's Disease: A Systematic Review of Preclinical Studies
Xiao-Wen Zhang et al. · International journal of molecular sciences · 2020

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology